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Rivaroxaban plasma levels in patients
admitted for bleeding events: insights from
a prospective study
Anne-Laure Sennesael1,3* , Anne-Sophie Larock2, Jonathan Douxfils3, Laure Elens4, Gabriel Stillemans4,
Martin Wiesen5, Max Taubert6, Jean-Michel Dogné3, Anne Spinewine1,2 and François Mullier7
Abstract
Background: Serious bleeding events have been frequently described in patients taking direct oral anticoagulants
(DOAC). In secondary analyses of phase 3 trials, DOAC plasma concentrations were shown to correlate with
bleeding outcomes. This study aimed to describe rivaroxaban plasma levels in patients admitted to the emergency
department (ED) for bleeding events. For each patient, risk factors for experiencing bleeding events were also
investigated.
Methods: This analysis was part of an observational study conducted in the ED of two teaching hospitals. Plasma
samples from 10 rivaroxaban-treated patients admitted for bleeding events were collected. Rivaroxaban plasma
concentrations were determined by calibrated chromogenic anti-Xa assay. The measured rivaroxaban levels were
then extrapolated at trough using a published population pharmacokinetic (PopPK) model, and compared to on-
therapy ranges observed in large clinical trials. For each patient, clinical, medication and ABCB1 genotype data were
collected.
Results: Rivaroxaban measurements varied from 5 to 358 ng/ml, with a post-intake delay ranging from 9 to 38 h.
At trough, estimated plasma concentrations were between 12 and 251 ng/ml (median value 94 ng/ml). Four
patients had higher-than-expected rivaroxaban levels. Inadequate dose regimen, excessive alcohol consumption
and lack of treatment reassessment were observed in several patients. Half of patients were taking ≥1 drug with
potential pharmacokinetics interactions (e.g. amiodarone, diltiazem), while half of patients were taking ≥1 drug
increasing the risk of bleeding. All 3 patients with available genotyping data and higher-than-expected rivaroxaban
levels were heterozygous or homozygous mutated for the ABCB1 1236C > T, 2677G > T, 3435 C > T and rs4148738
single nucleotide polymorphisms (SNP).
Conclusions: Rivaroxaban patients admitted to the ED for bleeding events showed highly variable plasma
concentrations. This analysis underlines the usefulness of rapid DOAC measurement and the value of PopPK models
to estimate concentrations at trough in a context where the post-intake delay is unmanageable. Close patient
follow-up, including renal function assessment and drug interactions review, is essential for bleeding risk
minimization.
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Background
Direct oral anticoagulants (DOAC) are increasingly
used in clinical practice, to prevent venous thrombosis
or thrombus formation in non-valvular atrial fibrillation
[1, 2]. However, serious bleeding events have been fre-
quently described for patients taking DOACs. In 2013–
2014, rivaroxaban and dabigatran were among the drugs
most commonly implicated in emergency department
(ED) admissions in the United States [3]. During phase 3
trials, risk of major bleeding of DOACs was similar to or
lower than warfarin, whereas the risk of intracranial
hemorrhage was substantially reduced [4, 5]. Recent ob-
servational studies have shown similar results in a real-life
setting [6].
Although DOACs do not require close therapeutic
monitoring, their measurement remains useful in spe-
cific clinical situations such as major bleeding and emer-
gency surgery [7]. Assessment of the individual response
may also benefit patients with suspected drug accumula-
tion or therapeutic failure. In secondary analyses of
phase 3 trials, DOAC plasma concentrations were shown
to correlate with bleeding outcomes [8–10]. Conversely,
a recent observational study has highlighted the relation-
ship between low DOAC levels, measured in the first
month of treatment, and the occurrence of thrombo-
embolic events [11]. However, a therapeutic range has
not been defined yet for each DOAC.
To our knowledge, few studies have investigated the
intensity of DOAC anticoagulation in patients presenting
to the ED for bleeding events. In the RE-VERSE AD
study, the median (unbound) dabigatran plasma concen-
tration was 110 ng/ml in patients with uncontrollable or
life-threatening bleeding, before the administration of
idarucizumab [12]. Bouget and Oger described DOAC
levels in 5 patients admitted for major bleeding [13].
However, measurements were not interpreted by taking
into account the post-intake delay and other influencing
individual factors.
In this study, we aimed to describe rivaroxaban
levels in patients admitted to the ED for bleeding
events. Measured plasma concentrations were extrap-
olated at trough using population pharmacokinetic
(popPK) modeling, and compared to the expected
on-therapy range. Several determinants of bleeding
were previously reported in rivaroxaban-treated pa-
tients, including older age, renal impairment or drug
interactions [14–17]. The inappropriate use of DOAC
has also been highlighted in this respect [18, 19]. In
addition, ABCB1 genetic polymorphisms have recently
been suggested to contribute to high rivaroxaban
levels in a patient admitted for gastrointestinal bleed-
ing [20]. Therefore, a second objective was to investi-
gate and discuss the presence of such risk factors for
bleeding events in our rivaroxaban patients.
Methods
Setting and population
This analysis was part of a prospective observational
cohort study, conducted in two teaching hospitals in
Belgium to assess the preventability of serious adverse
drug reactions related to the use of oral anticoagulants
[21]. We collected plasma samples from rivaroxaban pa-
tients admitted to the ED for a bleeding event, between
July 2015 and January 2016.
Rivaroxaban measurement
Blood sampling was performed closely after manage-
ment and inclusion of the patient in the study. Blood
was taken by antecubital venipuncture and collected into
0.109 M sodium citrate (9:1 v/v) tubes. Platelet-poor
plasma (PPP) was obtained from the supernatant frac-
tion after double centrifugation for 15 min at 1500 g at
room temperature. PPP was next aliquoted and frozen
at − 80 °C without delay. Frozen plasma samples ali-
quots were thawed by heating to 37 °C for at least
5 min just before experiments.
The following routine clotting assay was performed: pro-
thrombin time (PT) using RecombiPlasTin2G® (Werfen,
Lexington, USA; normal range 12.4–14.5 s). Rivaroxaban
plasma concentrations were estimated with the Biophen®
Direct Factor Xa Inhibitors (Biophen®DiXaI, Hyphen
BioMed, Neuville-Sur-Oise, France), a calibrated chromo-
genic anti-Xa assay. The procedure was performed on a
STA-R® Evolution analyzer according to the manufacturer
recommendations, using calibrators from Hyphen BioMed.
Commercial rivaroxaban anti-Xa assays have previously
demonstrated good accuracy (bias below 8%) and ac-
ceptable precision (inter-laboratory coefficients of vari-
ation (CV) 6–25%) [22]. A procedure dedicated to low
concentrations was applied to rivaroxaban plasma
concentrations < 50 ng/ml, where plasma samples were
diluted 1:8 in buffer and low concentrations standards
were used [23].
We extrapolated rivaroxaban plasma concentrations at
trough (i.e. 12 h and 24 h after the last drug intake for
twice daily and once daily regimen, respectively). To this
end, we used a Pop PK model that was previously devel-
oped to predict adequate discontinuation intervals in a
cohort of rivaroxaban patients scheduled for cardiac
catheterization [24]. Residual rivaroxaban concentrations
were described by a 2-compartment model with first-order
absorption and elimination. Results were then compared
to the expected on-therapy ranges at trough (5th–95th
percentiles): 12–137 ng/ml (rivaroxaban 20 mg) and 18–
136 ng/ml (rivaroxaban 15 mg) for stroke prevention in
non-valvular atrial fibrillation (NVAF), and 6–87 ng/ml for
treatment and secondary prevention of venous thrombo-
embolism (VTE) [25].
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Data collection
A comprehensive medication history was performed with
patients and/or relatives to collect sociodemographic,
clinical and medication data (including dose regimen, in-
dication and timing of the last rivaroxaban intake). Patient
renal function was estimated based on serum creatin-
ine on admission using Cockroft-Gault equation. We
reviewed electronic medical records and contacted
GPs, community pharmacists or relatives when neces-
sary. Bleeding severity was assessed using the Inter-
national Society on Thrombosis and Haemostasis
definition. Patient follow-up was undertaken to assess
3-month mortality.
Appropriateness of rivaroxaban prescribing was ana-
lyzed according to the Medication Appropriateness Index
(MAI) [26]. We applied a DOAC-specific form, previously
developed in a pilot study [27]. We documented the con-
comitant use of P-glycoprotein (P-gp) and CYP3A4 inhibi-
tors or inducers. Regarding potential pharmacodynamics
interactions, we considered other anticoagulants, anti-
platelet therapy, non-steroidal anti-inflammatory drugs
(NSAID), selective serotonin reuptake inhibitors (SSRI)
and serotonin-norepinephrine reuptake inhibitors (SNRI).
Patient adherence to anticoagulant therapy was evaluated
during medication history using an adapted version of the
Morisky Medication Adherence Scale [28].
ABCB1 genetic polymorphisms
For all patients except one (because of misunderstanding),
an additional blood sample was drawn in EDTA tube and
frozen at − 20 °C without delay until experiments. Genomic
DNA was extracted from whole blood, using QIAamp
DNA Blood Mini kit (Qiagen, CA, USA). The following
single nucleotide polymorphisms (SNP) of ABCB1 were
detected: rs1128503 (1236C >T, Gly412Gly), rs2032582
(2677G >T, Ala893Ser), rs1045642 (3435 C >T, Ile1145Ile)
and rs4148738. Allelic discrimination was performed by
TaqMan® (Applied Biosystems, CA, USA) Drug Metabolism
Genotyping Assays (C___7586662_10, C_11711720C_30,
C__15951365_20, C___1253813_10). Statistical analyses
were performed using JMP Pro 13.2.0 (SAS Institute, Cary,
NC, USA). Kruskal-Wallis tests were carried out to com-
pare estimated trough concentrations between different
genotypes. A p-value of less than 0.05 was considered
statistically significant.
Results
Study population
Plasma samples from 10 rivaroxaban patients were in-
cluded in this analysis. Median age of patients was
75 years, and 80% were female. Five patients had mod-
erate renal impairment on admission (creatinine clear-
ance < 60 ml/min). Indications of rivaroxaban therapy
were stroke prevention in NVAF (6/10) and treatment
and secondary prevention of VTE (4/10). Clinical charac-
teristics are detailed in Table 1 for each patient. The most
frequent adverse events were gastrointestinal bleeding
(4/10). Half of bleeding events were considered major
and half occurred spontaneously. Red blood cells transfu-
sion and prothrombin complex concentrates administra-
tion were operated in 4 and 1 patients, respectively. All
patients were alive at 3-month follow-up. Details of bleed-
ing events are presented in Table 2.
Rivaroxaban measurement
Measured rivaroxaban levels varied from 5 to 358 ng/ml,
with a delay since the last drug intake ranging from 9 to
38 h. PT was above the normal range in all patients with
rivaroxaban concentrations above 30 ng/ml (Table 3).
When using PopPK model, estimated plasma concentra-
tions at trough were between 12 and 251 ng/ml (median
value 94 ng/ml). Elimination clearance (CL/F) was be-
tween 2.0 and 7.9 L/h (median value 3.3 L/h). Measured
and extrapolated rivaroxaban concentrations are described
Table 1 Characteristics of rivaroxaban patients
No Sex, age
(years)
Weight
(kg)
BMI
(kg/m2)
CLcr
(ml/min)
Hb
(g/dl)
Indication Dosage Duration CHA2DS2-VASC HAS-BLED
1 M, 83 79 23.1 58 13.7 SPAF 20 mg OD ≤ 1 year 5 3
2 F, 70 N/K N/K N/K 3.1 SPAF 15 mg OD > 1 year 3 1
3 F, 87 65 25.7 48 6.4 VTE 20 mg OD < 30 days N/A 2
4 F, 67 80 24.7 53 7.2 SPAF 20 mg OD > 1 year 6 2
5 F, 77 63 25.2 61 14.3 SPAF 15 mg OD > 1 year 7 3
6 M, 66 100 35 86 15.6 SPAF 20 mg OD ≤ 1 year 2 2
7 F, 72 66 21.6 46 12.8 VTE 20 mg OD > 1 year N/A 3
8 F, 90 70 N/K 60 13.8 SPAF 15 mg OD N/K 6 1
9 F, 86 89 31.2 57 14.9 VTE 15 mg BID < 30 days N/A 1
10 F, 69 73 26.8 76 11.3 VTE 20 mg OD > 1 year N/A 2
BID twice-daily, BMI body mass index, CLcr creatinine clearance (Cockroft-Gault equation), Hb haemoglobin, OD once-daily, N/A not applicable, N/K not known,
SPAF stroke prevention in atrial fibrillation, VTE venous thromboembolism
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in Table 3 for each patient, as well as the elimination
clearance. Four patients had rivaroxaban levels at trough
higher than the expected on-therapy range (No 2, 3, 5, 9).
Analysis of risk factors for bleeding events
The analysis of rivaroxaban prescriptions revealed that
at least one criterion of the MAI was inappropriate in
8 of 10 patients. Three patients received an inad-
equate dosing regimen: 20 mg OD instead of 15 mg
OD (No 3, 7), and 15 mg BID instead of 20 mg OD
(No 9). Two of them had estimated trough concentra-
tion above the on-therapy range. Three patients had
an excessive alcohol consumption (≥ 2 units/day; No
1, 4, 7). Moreover, in two patients treated for VTE
prevention, treatment indication had not been reas-
sessed for years (No 3, 10).
Half of patients were taking at least 1 drug with po-
tential pharmacokinetic interactions (Table 3). Three
of them had higher-than-expected rivaroxaban plasma
concentrations at trough. The most frequent interact-
ing drugs were amiodarone and diltiazem. Moreover,
half of patients were taking at least 1 drug increasing
the risk of bleeding (Table 3). We mainly observed the
concomitant use of SSRI (n = 3) and NSAID (n = 2).
Regarding adherence to anticoagulant therapy, three
patients reported forgetting to take their medicine in
rare circumstances (No 1, 4, 7). One patient men-
tioned a variable time of intake (No 7).
ABCB1 genetic polymorphisms were analyzed in 9 of
10 patients. Genotyping data are presented in Table 4
for the ABCB1 1236C > T, 2677G > T, 3435 C > T and
rs4148738 SNP. Of the four patients with higher-tha-
n-expected rivaroxaban trough levels, three carried at
least one variant allele for each of these SNP (No 2,
3, 5 – blood sample not available for patient No 9).
However, no clear association between ABCB1 genotype
and estimated trough concentrations was observed
(p > 0.05).
Table 2 Characteristics, management and clinical outcomes of the 10 bleeding events
No Site of bleeding Bleeding severity Bleeding occurrence Management Length of stay (days) 90-day outcome
1 Hematuria NMCR Trauma – 0 Alive
2 Gastrointestinal Major Spontaneous RBC (3 units)a N/K N/K
3 Gastrointestinal Major Spontaneous RBC (2 units)a 3 Alive
4 Gastrointestinal Major Spontaneous RBC (3 units)a 1 Alive
5 Intracranial Major Trauma PCC (2500 IU) 43 Alive
6 Gastrointestinal NMCR Post-intervention – 0 Alive
7 Epistaxis NMCR Spontaneous – 2 Alive
8 Intracranial Major Trauma – 1 Alive
9 Hematuria NMCR Spontaneous – 0 Alive
10 Hematoma NMCR Trauma – 0 N/K
N/K not known, NMCR non-major clinically relevant, PCC prothrombin complex concentrates, RBC red blood cells. aTransfusion before blood sampling
Table 3 Measurement of rivaroxaban plasma concentrations
No Delay (h) PT (sec) Biophen® DiXaI (ng/ml) Estimated cc at
trough (ng/ml)
Clearance
(L/h)
Potential PK drug
interactions
Potential PD drug
interactions
1 28 18.7 84.8 98 3.3 – Ibuprofen
2 22 19.6 237.5 181a 2.0 Diltiazem (↑), Clarithromycin (↑) Escitalopram
3 38 15.4 70.8 125a 2.9 Simvastatin (↑) /
4 27 17.7 58.3 69 3.9 – Diclofenac, Escitalopram
5 27 N/K 139.4 134a 2.4 Amiodarone (↑) Aspirin
6 26 12.9 4.9 12 7.9 Amiodarone (↑) /
7 37 14.4 18.3 44 4.8 Diltiazem (↑) /
8 27 15.3 86.5 89 3.0 / /
9 9 26.0 357.8 251a 3.2 / /
10 13 N/K 184.7 72 3.9 / Duloxetine, Paroxetine
Biophen®DiXaI Biophen® Direct Factor Xa Inhibitors, cc concentration, N/K not known, PD pharmacodynamics, PK pharmacokinetics, PT prothrombin time (normal
range: 12.4–14.5 s), ↑: increased plasma concentrations, ↓: decreased plasma concentrations
aEstimated trough concentration above the on-therapy range (we considered higher-than-expected rivaroxaban levels for patient 5, as measured
concentration was higher than 136 ng/ml)
Sennesael et al. Thrombosis Journal  (2018) 16:28 Page 4 of 8
Discussion
In this analysis of 10 patients admitted for bleeding
events, we observed a large range of rivaroxaban levels.
The application of a previously published PopPK model
revealed that four patients had higher-than-expected
plasma concentrations at trough. Several risk factors for
bleeding were found at the individual level, including
older age, inappropriate use of rivaroxaban and drug
interactions.
To our knowledge, this is the first study to analyze in
depth rivaroxaban measurements in the context of
bleeding events. Inter-individual variability in DOAC ex-
posure has been previously investigated in routine care,
showing plasma levels outside the on-therapy range in
40% of rivaroxaban patients [29]. In four Italian anticoa-
gulation clinics, rivaroxaban measurements varied nearly
15-fold among NVAF patients, with a mean trough level
around 40 ng/ml [30]. This variability is in agreement
with our results, although we estimated a higher median
trough concentration (94 ng/ml). This reflects a delayed
rivaroxaban clearance in our bleeding patients (median
CL/F 3.3 L/h, compared to 4.9 L/h in patients scheduled
for cardiac catheterization or 6.1 L/h in AF patients as
previously reported) [24, 31]. Two recent cohort studies
have shown median rivaroxaban levels of 124 ng/ml in
patients with severe bleeding events, and 102 ng/ml in
patients admitted for intracranial hemorrhage [32, 33].
Delay since the last drug intake was 12 h (median value)
in the former case, and less than 24 h for most patients
in the latter case.
Rivaroxaban measurement for bleeding management
The management of DOAC-related bleeding includes
the temporary discontinuation of the oral anticoagulant,
supportive measures and the administration of reversal
agents, depending on the severity of the event [34, 35].
Andexanet alpha has recently been approved by the
FDA to reverse the anticoagulant effect of rivaroxaban,
while prothrombin complex concentrates were also sug-
gested as an alternative [36–38]. In this context, rapid
laboratory measurement may provide valuable assistance
to warrant and monitor antidote administration, or man-
age urgent interventions [7].
In the present study, we observed that PT was pro-
longed in all patients with clinically relevant concentra-
tions (> 30 ng/ml) of rivaroxaban. However, we
employed a sensitive thromboplastin reagent (Recombi-
PlasTin 2G®) for the assay [39]. A nationwide Belgian
survey has previously highlighted a wide variation in re-
sponse to rivaroxaban according to the reagent used
[40]. Commercial specific assays are currently available
for all DOACs [41]. They are more accurate but require
calibrators and controls. Turnaround times around
30 min have nevertheless been reported in a daily prac-
tice context [42, 43].
Factors associated with an increased risk of bleeding
Several risk factors for bleeding events were highlighted
in our 10 rivaroxaban patients. First, half of them were
older than 75 years, and half of them had moderate renal
impairment. Older age and renal insufficiency were pre-
viously demonstrated as contributing factors to major
bleeding in rivaroxaban patients [14]. Recently, glomerular
filtration rates below 60 ml/min have been independently
associated with higher-than-expected residual rivaroxaban
levels in a perioperative setting [44]. This is not surprising
since one third of the rivaroxaban dose is eliminated un-
changed by the kidneys [25]. However, in our analysis,
only two patients with moderate renal impairment had
trough concentrations above the on-therapy range. Sec-
ond, despite the highest convenience and fixed-dose regi-
men of DOAC, some of our patients did not receive the
appropriate dose of rivaroxaban. In particular, one patient
(No 9) was still taking rivaroxaban 15 mg BID while the
21-day treatment phase of VTE had been completed. Yao
and colleagues highlighted that patients with indication
for dose reduction were often potentially overdosed, lead-
ing to an increased risk of major bleeding [19].
Drugs interactions with P-gp or CYP3A4 inhibitors were
frequent in our patients, as previously reported [32, 45].
One patient (No 2) was taking diltiazem and clarithromy-
cin, two inhibitors of both P-gp and CYP3A4. He had an
estimated rivaroxaban level of 181 ng/ml at trough, ex-
ceeding the 95th percentile of the on-therapy range
(136 ng/ml). In healthy volunteers, clarithromycin has
been shown to promote a 2-fold increase in rivaroxaban
exposure [46]. Similarly, we extrapolated a rivaroxaban
trough concentration of 125 ng/ml in a patient taking sim-
vastatin (No 3). This P-gp inhibitor has been associated
with a higher risk of major bleeding in patients taking
dabigatran [47]. Pharmacodynamic interactions were also
Table 4 ABCB1 genotyping in 10 rivaroxaban patients with
bleeding events
No 1236C > T 2677G > T 3435C > T rs4148738
1 CC GG CC AA
2 CT GT CT GA
3 CT GT CT GA
4 TT TT CT GG
5 CT GT TT GA
6 TT TT TT GG
7 CT GT TT GA
8 TT TT TT GG
9 N/K N/K N/K N/K
10 CC GG CT AA
N/K not known. Patients with higher-than-expected rivaroxaban levels are
shown in bold
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widely observed. Aspirin has often no valid indication
in anticoagulated patients, while combination therapy
has been shown to increase the risk of major bleeding
[16, 48]. A similar increase was associated with the
addition of SSRIs, the most prescribed class of antide-
pressants [49].
An original aspect of this work was the investigation of
several ABCB1 polymorphisms. All 3 patients with higher-
than-expected rivaroxaban levels and available genotyping
data were at least heterozygous mutated for the 1236C >T,
2677G >T, 3435C >T and rs4148738 SNP. Previous experi-
ments have shown that the 1236 T–2677 T-3435 T variant
haplotype decreased ABCB1 expression or transport to-
wards several drugs such as anticancer agents [50–52].
These results support our observations, as a decreased ef-
flux of rivaroxaban may have led to drug accumulation.
However, in a recent study conducted in 60 healthy volun-
teers, the 1236 T–2677 T-3435 T haplotype was not a sig-
nificant determinant of rivaroxaban pharmacokinetics [46].
This strengthens the need for additional studies to clarify
the impact of ABCB1 polymorphisms on rivaroxaban trans-
port. Indeed, our findings might also be due to the high fre-
quency of the variant genotype 1236 T–2677 T-3435 T (up
to 50% of the Caucasian population is expected to heterozy-
gous mutated). Furthermore, these three patients were also
receiving concomitant interacting medications, as previ-
ously discussed.
The study presents several limitations. First, statis-
tical analysis was limited by the small number of
plasma samples collected. However, this allowed an
in-depth analysis of rivaroxaban measurements, in-
cluding clinical, medication and genetic characteristics
at the individual level. Second, three patients (No 2–
4) were transfused with red blood cells (RBC) before
sampling. For these patients, we cannot exclude that
rivaroxaban measurements were not influenced by
fluid volume or factor Xa content of packed RBC.
However, Biophen®DiXaI was designed for minimizing
the interference of plasma factors. Third, estimation
of renal function was only based on serum creatinine
on admission, as previous laboratory results performed in
primary care were not available. Finally, the Pop PK model
we used assumed no variability in the volume of distribu-
tion, while inter-individual variability in V/F was 18% in
another Pop PK model from AF patients [31]. However,
simulations were previously performed and showed the
limited influence of this variability on predicted exposure
estimates.
Conclusion
In conclusion, rivaroxaban patients admitted to the ED
for bleeding events showed highly variable plasma con-
centrations and a delayed elimination clearance. This
underlines the usefulness of rapid DOAC measurement
to assess contribution to the adverse event, manage
urgent procedures or warrant antidote administration.
Close patient follow-up, including renal function assess-
ment and drug interactions review, is essential for bleed-
ing risk minimization. Further studies are needed to
investigate the impact of ABCB1 polymorphisms on
DOAC transport.
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